The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

Recent advances in RAS-targeted therapies revolutionize treatment for gastrointestinal cancers, promising improved outcomes and new clinical strategies for oncologists.

FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome marks a major milestone for Soleno Therapeutics.

Operator: Good day, everyone, and thank you for standing by. Welcome to the Vistagen Therapeutics Fiscal Year-End 2025 ...

FDA approvals and long-term study results, showcasing advancements in cancer treatments, and patient care strategies.

A growing body of research demonstrating the safety and effectiveness of self-managed abortion with pills, coupled with the ...

Patients Demonstrate Significant Knowledge Gaps in Treatment Options, Leading to Lost Hope and Treatment Discontinuation Over ...